Xin Wei, Rhodes Daniel R, Ingold Collette, Chinnaiyan Arul M, Rubin Mark A
Department of Pathology and the Comprehensive Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Am J Pathol. 2003 Jan;162(1):255-61. doi: 10.1016/S0002-9440(10)63816-3.
Hormone refractory prostate cancer (PCa) is invariably lethal despite aggressive clinical treatment strategies. Detection strategies are needed to identify aggressive PCa before it becomes widely disseminated. Recently, two studies identified annexin 1 and 7 as potential biomarkers in the development of PCa progression. The annexins are a group of calcium-binding structural proteins that may play a role in the regulation of membrane trafficking, cellular adhesion, and cell signaling. Therefore the goal of this study is to simultaneously characterize the multiple members of the annexin family of genes in advanced PCa. Prostate samples from men with advanced hormone refractory PCa were compared to samples of hormone-naïve PCa and noncancerous prostate tissue. Samples from 15 patients with advanced hormone refractory PCa were used. To examine the annexin family, gene expression profiles from 21 noncancerous prostate tissues, 16 clinically localized PCas, and 20 hormone refractory PCa samples were used. By cDNA microarray analysis, annexins 1, 2, 4, 7, and 11 were significantly decreased in hormone refractory PCa when compared to localized hormone-naïve PCa with 2.2-, 1.5-, 1.3-, 1.4-, and 1.8-fold decreases, respectively (all P values <0.05). Interstudy validation of annexin family transcript expression was performed by meta-analysis of three other published prostate profiling studies. High-density tissue microarrays were used to validate a subset of annexins at the protein level by immunohistochemistry. Tissue microarray analysis revealed a significant decrease in protein expression for annexins 1, 2, 4, 7, and 11 in hormone refractory PCa as compared to localized PCa with 1.68-, 2.46-, 2.52-, and 3.01-fold decreases, respectively (Kruskal Wallis test, all P values P < 0.05). However, no significant differences were detected between the clinically localized PCa and noncancerous prostate tissues. These findings suggest that down-regulation of several members of the annexin family may contribute to PCa tumorigenesis. Annexins 1, 2, 4, 7, and 11 may play a role in tumor progression through distinct mechanisms or, alternatively, they may have redundant tumor suppressor activities. This study also suggests that a meta-analysis of existing gene expression data is useful in confirming findings from individual studies. Finally, down-regulation of several annexin family members may play a role in the development of the lethal PCa phenotype.
激素难治性前列腺癌(PCa)尽管采用了积极的临床治疗策略,但最终仍会致命。需要检测策略来在侵袭性PCa广泛扩散之前将其识别出来。最近,两项研究将膜联蛋白1和7确定为PCa进展过程中的潜在生物标志物。膜联蛋白是一组钙结合结构蛋白,可能在膜运输、细胞黏附和细胞信号传导的调节中发挥作用。因此,本研究的目的是同时对晚期PCa中膜联蛋白家族基因的多个成员进行特征分析。将晚期激素难治性PCa男性患者的前列腺样本与未接受激素治疗的PCa样本及非癌性前列腺组织样本进行比较。使用了15例晚期激素难治性PCa患者的样本。为了研究膜联蛋白家族,使用了来自21个非癌性前列腺组织、16个临床局限性PCa和20个激素难治性PCa样本的基因表达谱。通过cDNA微阵列分析,与局限性未接受激素治疗的PCa相比,激素难治性PCa中膜联蛋白1、2、4、7和11显著降低,分别降低了2.2倍、1.5倍、1.3倍、1.4倍和1.8倍(所有P值<0.05)。通过对其他三项已发表的前列腺分析研究进行荟萃分析,对膜联蛋白家族转录本表达进行了研究间验证。使用高密度组织微阵列通过免疫组织化学在蛋白质水平验证了一部分膜联蛋白。组织微阵列分析显示,与局限性PCa相比,激素难治性PCa中膜联蛋白1、2、4、7和11的蛋白质表达显著降低,分别降低了1.68倍、2.46倍、2.52倍和3.01倍(Kruskal Wallis检验,所有P值P<0.05)。然而,在临床局限性PCa和非癌性前列腺组织之间未检测到显著差异。这些发现表明,膜联蛋白家族的几个成员下调可能有助于PCa肿瘤发生。膜联蛋白1、2、4、7和11可能通过不同机制在肿瘤进展中发挥作用,或者它们可能具有冗余的肿瘤抑制活性。本研究还表明,对现有基因表达数据进行荟萃分析有助于确认个体研究的结果。最后,几个膜联蛋白家族成员的下调可能在致命性PCa表型的发展中起作用。